Objective: The present study determined the role of DEP domain containing mTOR-interacting protein (DEPTOR) in the proliferation, apoptosis and chemosensitivity of RPMI-8226 multiple myeloma cells, using small hairpin RNA (shRNA) to knock down DEPTOR gene expression in vitro.

Methods: DEPTOR mRNA and protein levels in RPMI-8226 cells treated with DEPTOR-specific shRNA were evaluated by reverse transcription-polymerase chain reaction and Western blotting. Expression of apoptosis-associated proteins (including cleaved caspase-3 and cleaved poly-ADP ribose polymerase [PARP]) and activation of the phosphatidylinositol 3-kinase (PI3K)/v-akt murine thymoma viral oncogene homologue 1 (AKT) signalling pathway were detected by Western blotting.

Results: Transfection of DEPTOR-specific shRNA successfully knocked down DEPTOR gene expression in transfected RPMI-8226 cells. These transfected cells, together with control RPMI-8226 cells, were treated with 20 µmol/l melphalan for 24 h. Knockdown of DEPTOR exacerbated melphalan-induced growth inhibition and apoptosis, increased levels of cleaved caspase-3 and cleaved PARP, and reduced levels of phosphor-AKT.

Conclusion: Downregulation of DEPTOR inhibited proliferation and increased chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting the PI3K/AKT pathway.

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300060513480920DOI Listing

Publication Analysis

Top Keywords

rpmi-8226 cells
20
multiple myeloma
12
knockdown deptor
8
chemosensitivity melphalan
8
melphalan human
8
human multiple
8
myeloma rpmi-8226
8
cells inhibiting
8
inhibiting pi3k/akt
8
deptor gene
8

Similar Publications

Peroxiredoxin 6 (PRDX6) is one of the Peroxiredoxin family members with only 1-Cys, using glutathione as the electron donor to reduce peroxides in cells. PRDX6 has been frequently studied and its expression was associated with poor prognosis in many tumors. However, the expression of PRDX6 in multiple myeloma (MM) and its relevance with MM remain unclear.

View Article and Find Full Text PDF

Reduced elastin in multiple myeloma niche promotes cell proliferation.

Exp Cell Res

January 2025

Oncogenetics Laboratory, Meir Medical Center, Tchernichovsky St 59, Kfar Saba, Israel; Faculty of Medical and Health Sciences, Tel Aviv University, PO Box 39040, Tel Aviv, Tel Aviv, Israel. Electronic address:

Multiple myeloma (MM) malignant plasma cells accumulate in the bone marrow (BM) where their interactions with the microenvironment promote disease progression and drug resistance. Previously, we have shown that bone marrow mesenchymal stem cells (BM-MSCs) (MM and normal donors- ND) derived extracellular matrix (ECM) affected MM cell lines differentially with a pro-MM effect attributed to MM-MSCs' ECM. Here we studied the composition of BM-MSC's ECM (ND versus MM) with focus on elastin (ELN).

View Article and Find Full Text PDF

The current comprehensive study showcases a meticulous synthesis of novel class of α-benzilmonoxime thiocarbohydrazide (BMOTC) derivatives, and manifesting their multifaceted potential as antibacterial, antifungal, and anticancer agents. The synthesis of target compounds was performed in three phases using literature methods. In the first step, benzilmonoxime is synthesized using benzil and hydroxyl amine hydrochloride, followed by benzilmonoxime imine using thiocarbohydrazide.

View Article and Find Full Text PDF
Article Synopsis
  • Multiple myeloma (MM) is a type of blood cancer marked by excessive production of plasma cells that release antibodies, and current research on treatments like Raddeanin A (RA) focuses mainly on solid tumors, leaving a gap in understanding its effects on MM specifically.
  • RA, derived from Anemone raddeana regel, shows promising anti-tumor effects, and this study explores how it may inhibit MM cell growth through network pharmacology and experimental methods, revealing significant interactions with the MAPK signaling pathway.
  • Experimental results demonstrate that RA effectively slows MM cell proliferation, induces apoptosis, alters mitochondrial function, and impacts the expression of key proteins involved in cell growth and survival, suggesting a powerful potential for RA as a treatment for multiple my
View Article and Find Full Text PDF

Complement-dependent cytotoxicity (CDC) is a primary mechanism-of-action of monoclonal antibody (mAb) immunotherapies used to treat haematological cancers, including rituximab and daratumumab. However, mAb efficacy may be limited by reduced bioavailability of complement C1q - which activates the complement classical pathway following interactions with mAb-opsonised target cells. C1q is secreted by phagocytes upon recruitment to sites of muscle damage to facilitate muscular repair, hence we hypothesised that muscle damaging exercise may increase C1q 'spill-over' into blood.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!